Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher L Corless

Showing results (191-200 of 208) with videos related to

Pageof 21
Sort By:
JAMA Oncology|February 15, 2017
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033Michael C Heinrich, Cathryn Rankin, Charles D Blanke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumorMichael C Heinrich, Christopher L Corless, George D Demetri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2023
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorMichael C Heinrich, Christopher L Corless, George D Demetri, et al.
Archives of Pathology & Laboratory Medicine|August 4, 2006
Interobserver agreement in hepatitis C grading and staging and in the Banff grading schema for acute cellular rejection: the "hepatitis C 3" multi-institutional trial experienceGeorge J Netto, David L Watkins, James W Williams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2021
Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic ResponseMayra Yebra, Shruti Bhargava, Avi Kumar, et al.
The Journal of Pathology|November 6, 2009
Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumoursSubbaya Subramanian, Venugopal Thayanithy, Robert B West, et al.
The Journal of Molecular Diagnostics : JMD|December 15, 2019
Multi-Institutional Evaluation of Interrater Agreement of Variant Classification Based on the 2017 Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in CancerDeepika Sirohi, Robert L Schmidt, Dara L Aisner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT InhibitionRichard D Carvajal, Donald P Lawrence, Jeffrey S Weber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trialAriel Lopez-Chavez, Anish Thomas, Arun Rajan, et al.
Journal of Translational Medicine|December 16, 2016
FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumorsEileen Shi, Juliann Chmielecki, Chih-Min Tang, et al.
Pageof 21

Showing results (191-200 of 208) with videos related to

Sort By:
Pageof 21
JAMA Oncology|February 15, 2017
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033Michael C Heinrich, Cathryn Rankin, Charles D Blanke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumorMichael C Heinrich, Christopher L Corless, George D Demetri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2023
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorMichael C Heinrich, Christopher L Corless, George D Demetri, et al.
Archives of Pathology & Laboratory Medicine|August 4, 2006
Interobserver agreement in hepatitis C grading and staging and in the Banff grading schema for acute cellular rejection: the "hepatitis C 3" multi-institutional trial experienceGeorge J Netto, David L Watkins, James W Williams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2021
Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic ResponseMayra Yebra, Shruti Bhargava, Avi Kumar, et al.
The Journal of Pathology|November 6, 2009
Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumoursSubbaya Subramanian, Venugopal Thayanithy, Robert B West, et al.
The Journal of Molecular Diagnostics : JMD|December 15, 2019
Multi-Institutional Evaluation of Interrater Agreement of Variant Classification Based on the 2017 Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in CancerDeepika Sirohi, Robert L Schmidt, Dara L Aisner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT InhibitionRichard D Carvajal, Donald P Lawrence, Jeffrey S Weber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trialAriel Lopez-Chavez, Anish Thomas, Arun Rajan, et al.
Journal of Translational Medicine|December 16, 2016
FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumorsEileen Shi, Juliann Chmielecki, Chih-Min Tang, et al.
Pageof 21